Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915414 | 0.86 | ALDH1A1 (0.66) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL1001018 | 0.81 | HSD11B1 (0.69) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL11438483 | 0.80 | MAPT (0.58) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL11438487 | 0.80 | MAPT (0.58) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL777601 | 0.79 | PSIP1 (0.67) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| Hydrochloric Acid SCHEMBL10584023 | 0.79 | HSD11B1 (0.67) | MAPTHSD11B1L3MBTL1POLBKDM4E | |
| SCHEMBL24590151 | 0.79 | HSD11B1 (0.68) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL1232793 | 0.79 | HDAC1 (0.57) | MAPTHSD11B1L3MBTL1PSIP1POLB | |
| SCHEMBL7321453 | 0.78 | POLB (0.66) | MAPTHSD11B1PSIP1POLBKMT2A | |
| SCHEMBL1161573 | 0.78 | HSD11B1 (0.65) | MAPTHSD11B1L3MBTL1PSIP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060893-A1 | PYRROLOPYRIDINE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | MAPT 2939/4885HSD11B1 3405/4885L3MBTL1 869/4885 |
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | MAPT 1529/4885HSD11B1 3960/4885L3MBTL1 3492/4885 |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | KCNJ2, KCNN2, KCNJ1 | MAPT 1450/4885HSD11B1 4062/4885L3MBTL1 3578/4885 |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | MAPT 3949/4885HSD11B1 2454/4885L3MBTL1 1654/4885 |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | MAPT 1529/4885HSD11B1 3960/4885L3MBTL1 3492/4885 |
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | MAPT 3949/4885HSD11B1 2454/4885L3MBTL1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.